EMA Application withdrawn: Pemetrexed ditromethamine Hospira (pemetrexed ditromethamine)

View source ↗

Summary

The EMA withdrew the application for pemetrexed ditromethamine Hospira, a pemetrexed conjugate, for mesothelioma and non-small cell lung carcinoma indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• pemetrexed ditromethamine Hospira (pemetrexed ditromethamine)

Snippet

Status: Application withdrawn. Therapeutic area: Mesothelioma;Carcinoma, Non-Small-Cell Lung. Decision date: 14/10/2016